Global Conjugate Vaccines Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2028
“Global Conjugate Vaccines Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028” is a recent report generated by MarketResearch.biz. The global conjugate vaccines market report has been segmented on the basis of type, disease indication, pathogen type, end user, and region.
Global Conjugate Vaccines Market: Overview
Conjugate vaccines are vaccines contains bacterial capsule polysaccharide and used for infectious diseases. It improves immunogenic property of polysaccharide. Such types of vaccines are used to immunize infants and children against invasive disease which are caused by Streptococcus pneumoniae, Neisseria meningitidis, H. influenzae, and Hib bacteria. Conjugate vaccines are currently in use for children against pneumococcal bacterial infections are made using this technique.
Global Conjugate Vaccines Market: Dynamics
Increasing government initiatives across various countries, technological advancements, improvement in vaccine formulation, and rising incidences of infectious diseases are major factors expected to drive growth of the global market over the forecast period.
In addition, rising investment in research and development activities by key players operating in the target market, increasing demand for vaccination, and increasing preference towards immunization programs are some other factors expected to further fuel growth of the target market over the forecast period.
Moreover, increasing number of health awareness programs in order to promote vaccination and prevention of infectious diseases is another factor expected to boost growth of the target market over the forecast period.
However, lack of availability in remote areas and lengthy and difficult production process of conjugate vaccine are major factors expected to restrain growth of the global market over the forecast period.
Increasing research and development activities for the development of technologically advanced and innovative products and development of strategic business activities such as mergers, acquisitions, etc. are expected to create lucrative opportunities for the global market over the forecast period.
Global Conjugate Vaccines Market: Segment Analysis
Among the type segments, the monovalent conjugate vaccines segment is expected to register significant growth in terms of revenue over the forecast period, owing to rising awareness and availability of high-quality vaccines by manufacturers in this market.
Among the disease indication segments, the diphtheria tetanus and pertussis segment is expected to register significant share in terms of revenue over the forecast period, owing to its high prevalence.
Global Conjugate Vaccines Market: Regional Analysis
The market in North America is expected to dominate in the global market over the forecast period, owing to increasing demand for meningococcal, pneumococcal vaccines, and related conjugate vaccines across various countries in this region.
The market in Europe is expected to register second-highest growth in terms of revenue over the forecast period, owing to increasing government focus on research and availability of funds for research and development activities across various countries in this region.
The market in Asia Pacific is expected to register significant growth in terms of CAGR over the forecast period, owing to increasing government initiatives, rising initiatives by various organizations such as World Health Organization and GAVI across various countries in this region.
Global Conjugate Vaccines Market Segmentation:
Segmentation by type:
- Monovalent Conjugate Vaccines
- Multivalent Conjugate Vaccines
Segmentation by disease indication:
- Diphtheria Tetanus and Pertussis (DTP)
Segmentation by pathogen type:
- Bacterial Conjugate Vaccine
- Viral Conjugate Vaccine
- Combination (Viral and Bacterial) Conjugate Vaccine
Segmentation by end user:
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2028 Revenue in US$
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- SutroVax, Inc.
- Taj Pharmaceuticals Limited
- Sanofi Pasteur SA
- Sinovac Biotech Co., Ltd.
- Bharat Biotech International Limited
- Biological E. Limited
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!